Cwm LLC Cuts Stock Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Cwm LLC decreased its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 97.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,113 shares of the biopharmaceutical company’s stock after selling 50,854 shares during the quarter. Cwm LLC’s holdings in Halozyme Therapeutics were worth $41,000 as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of the business. Artisan Partners Limited Partnership lifted its holdings in shares of Halozyme Therapeutics by 3.4% in the 3rd quarter. Artisan Partners Limited Partnership now owns 7,712,874 shares of the biopharmaceutical company’s stock valued at $294,632,000 after acquiring an additional 253,363 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in shares of Halozyme Therapeutics by 0.9% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,698,359 shares of the biopharmaceutical company’s stock worth $64,877,000 after purchasing an additional 15,902 shares during the period. Allspring Global Investments Holdings LLC increased its position in shares of Halozyme Therapeutics by 174.5% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 887,274 shares of the biopharmaceutical company’s stock valued at $33,894,000 after purchasing an additional 563,989 shares during the last quarter. Kennedy Capital Management LLC raised its holdings in Halozyme Therapeutics by 4.7% during the 3rd quarter. Kennedy Capital Management LLC now owns 646,475 shares of the biopharmaceutical company’s stock valued at $24,695,000 after buying an additional 28,880 shares during the period. Finally, Principal Financial Group Inc. lifted its position in Halozyme Therapeutics by 10.9% in the third quarter. Principal Financial Group Inc. now owns 590,651 shares of the biopharmaceutical company’s stock worth $22,563,000 after buying an additional 58,123 shares during the last quarter. Institutional investors own 97.79% of the company’s stock.

Insider Transactions at Halozyme Therapeutics

In related news, SVP Michael J. Labarre sold 10,000 shares of Halozyme Therapeutics stock in a transaction that occurred on Tuesday, March 12th. The shares were sold at an average price of $41.64, for a total transaction of $416,400.00. Following the transaction, the senior vice president now directly owns 156,558 shares of the company’s stock, valued at $6,519,075.12. The sale was disclosed in a filing with the SEC, which is accessible through this link. In the last quarter, insiders sold 30,000 shares of company stock valued at $1,196,800. Company insiders own 2.70% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on HALO shares. StockNews.com raised shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, February 23rd. Benchmark reaffirmed a “buy” rating and set a $50.00 target price on shares of Halozyme Therapeutics in a research note on Tuesday, April 16th. TD Cowen initiated coverage on Halozyme Therapeutics in a report on Thursday, February 29th. They issued an “outperform” rating and a $54.00 price target on the stock. The Goldman Sachs Group dropped their price objective on Halozyme Therapeutics from $45.00 to $40.00 and set a “neutral” rating for the company in a report on Thursday, January 18th. Finally, JMP Securities reduced their target price on Halozyme Therapeutics from $72.00 to $71.00 and set a “market outperform” rating on the stock in a research note on Wednesday. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $53.14.

Halozyme Therapeutics Trading Up 4.4 %

HALO opened at $43.84 on Friday. The company has a quick ratio of 5.50, a current ratio of 6.64 and a debt-to-equity ratio of 17.89. The stock’s fifty day moving average is $40.17 and its two-hundred day moving average is $38.05. The company has a market capitalization of $5.57 billion, a P/E ratio of 20.78, a PEG ratio of 0.47 and a beta of 1.26. Halozyme Therapeutics, Inc. has a 52 week low of $31.05 and a 52 week high of $45.00.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings results on Tuesday, February 20th. The biopharmaceutical company reported $0.75 EPS for the quarter, missing the consensus estimate of $0.77 by ($0.02). Halozyme Therapeutics had a net margin of 33.96% and a return on equity of 248.20%. The firm had revenue of $230.04 million for the quarter, compared to analysts’ expectations of $235.25 million. Analysts forecast that Halozyme Therapeutics, Inc. will post 3.43 earnings per share for the current year.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.